Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
OP12: Targeting inflammation in ulcerative colitis by inhibiting glucose uptake
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Roswitha Gropp
Created: Tuesday, 28 May 2019, 3:32 PM
Immunology, Lymphocyte, Macrophage, T cell
Files: 1
OP12: The incidence and disease course of Perianal Crohn’s Disease - A Danish nationwide cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Mads Damsgaard Wewer
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP13: Glyco-fingerprint as a relevant risk factor on colitis-associated cancer
Year: 2020
Source: ECCO'20 Vienna
Authors: Ana Dias
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP13: Molecular response to ustekinumab in moderate-to-severe ulcerative colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Katherine Li
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Ustekinumab, Genetics, Genetic factors
Files: 1
OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately-to-severely active ulcerative colitis: data from the U-ACHIEVE study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: William J Sandborn
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, JAK inhibitors
Files: 1
OP14: Risk of colorectal cancer diagnosis and colorectal cancer mortality in Crohn’s Disease: A Scandinavian population-based cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Ola Olen
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP15: Multi-omic data integration with network analysis reveal underlying molecular mechanisms driving Crohn’s Disease heterogeneity
Year: 2020
Source: ECCO'20 Vienna
Authors: Bram Verstockt
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild to moderate ulcerative colitis: efficacy results
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Stuart Bloom
Created: Tuesday, 28 May 2019, 3:32 PM
5-ASA, Anti-TNF agents, Ciclosporin, Infliximab
Files: 1
OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Mayte Suarez-Farinas
Created: Tuesday, 28 May 2019, 3:32 PM
Crohn’s disease, Ulcerative colitis, CRP and other serum biomarkers, Transcriptomics
Files: 1
OP17: Protein intakes and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD).
Year: 2020
Source: ECCO'20 Vienna
Authors: Catherine Dong
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in pediatric patients with Crohn’s disease: The pediatric Crohn's disease adalimumab level-based optimization treatment (PAILOT) trial
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Amit Assa
Created: Tuesday, 28 May 2019, 3:32 PM
Adalimumab, Pharmacokinetics, Treat to target, Paediatric, Outcome measures
Files: 1
OP18: Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn's Disease: The SuPREMe-CD Study
Year: 2020
Source: ECCO'20 Vienna
Authors: Gaetano Luglio
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Yael Haberman
Created: Tuesday, 28 May 2019, 3:32 PM
Microbiota, Natural history, Ulcerative colitis, Calprotectin and other faecal biomarkers, Prognosis, Corticosteroids, Infliximab, Vedolizumab, Paediatric, Microbiota, Outcome measures
Files: 1
OP19: Perinatal factors do not affect paediatric Inflammatory Bowel Disease risk: A Scottish nationwide cohort study using administrative health data 1981-2017
Year: 2020
Source: ECCO'20 Vienna
Authors: Christopher Burgess
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP20: Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn’s Disease.
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Amy Lewis
Created: Tuesday, 28 May 2019, 3:32 PM
Files: 1
OP21: ABX464 is safe and efficacious in a proof of concept study in ulcerative colitis patients
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Jean-Marc Steens
Created: Tuesday, 28 May 2019, 3:32 PM
Files: 1
OP21: Positivity thresholds of a total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
Year: 2020
Source: ECCO'20 Vienna
Authors: Nicholas Alexander Kennedy
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Jieun Shin
Created: Tuesday, 28 May 2019, 3:32 PM
Epigenetics, Immunology, Macrophage, T cell
Files: 1
OP23: Efficacy and safety of vedolizumab SC in patients with Moderately to Severely active Crohn’s Disease: Results of the VISIBLE 2 study
Year: 2020
Source: ECCO'20 Vienna
Authors: Séverine Vermeire
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP24: A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s Disease and Ulcerative Colitis
Year: 2020
Source: ECCO'20 Vienna
Authors: Shomron Ben-Horin
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1